9,710 Shares in Denali Therapeutics Inc. (NASDAQ:DNLI) Bought by Integrated Advisors Network LLC

Integrated Advisors Network LLC bought a new position in Denali Therapeutics Inc. (NASDAQ:DNLI) during the third quarter, according to its most recent filing with the SEC. The firm bought 9,710 shares of the company’s stock, valued at approximately $283,000.

A number of other large investors also recently modified their holdings of DNLI. GAMMA Investing LLC lifted its holdings in shares of Denali Therapeutics by 879.5% in the 2nd quarter. GAMMA Investing LLC now owns 2,057 shares of the company’s stock worth $48,000 after purchasing an additional 1,847 shares in the last quarter. PNC Financial Services Group Inc. raised its position in Denali Therapeutics by 48.1% in the 4th quarter. PNC Financial Services Group Inc. now owns 2,486 shares of the company’s stock valued at $53,000 after buying an additional 807 shares during the last quarter. CWM LLC raised its position in Denali Therapeutics by 43.6% in the 3rd quarter. CWM LLC now owns 2,153 shares of the company’s stock valued at $63,000 after buying an additional 654 shares during the last quarter. Headlands Technologies LLC purchased a new stake in Denali Therapeutics in the 1st quarter valued at $88,000. Finally, SG Americas Securities LLC purchased a new stake in Denali Therapeutics in the 1st quarter valued at $147,000. 92.92% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. JPMorgan Chase & Co. lowered their price target on Denali Therapeutics from $29.00 to $28.00 and set an “overweight” rating for the company in a research report on Friday, October 11th. Wedbush lowered their price target on Denali Therapeutics from $30.00 to $26.00 and set an “outperform” rating for the company in a research report on Friday, August 2nd. Citigroup raised their target price on Denali Therapeutics from $26.00 to $32.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. Cantor Fitzgerald lowered Denali Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, October 7th. Finally, Bank of America raised their target price on Denali Therapeutics from $25.00 to $29.00 and gave the company a “buy” rating in a research report on Wednesday, September 4th. Three research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, Denali Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $38.90.

Denali Therapeutics Stock Performance

Shares of DNLI opened at $27.05 on Friday. The business has a 50-day moving average of $27.33 and a 200 day moving average of $23.01. Denali Therapeutics Inc. has a fifty-two week low of $14.56 and a fifty-two week high of $32.13. The firm has a market cap of $3.87 billion, a P/E ratio of -9.49 and a beta of 1.38.

Denali Therapeutics (NASDAQ:DNLI) last issued its earnings results on Thursday, August 1st. The company reported ($0.59) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.09. The company had revenue of $1.00 million during the quarter, compared to the consensus estimate of $10.00 million. During the same quarter in the prior year, the business earned $1.30 EPS. The firm’s revenue for the quarter was down 99.7% compared to the same quarter last year. As a group, research analysts predict that Denali Therapeutics Inc. will post -2.53 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Denali Therapeutics news, CEO Ryan J. Watts sold 40,000 shares of the firm’s stock in a transaction dated Friday, October 18th. The stock was sold at an average price of $27.69, for a total value of $1,107,600.00. Following the completion of the transaction, the chief executive officer now owns 235,807 shares in the company, valued at $6,529,495.83. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CEO Ryan J. Watts sold 40,000 shares of Denali Therapeutics stock in a transaction dated Friday, October 18th. The stock was sold at an average price of $27.69, for a total transaction of $1,107,600.00. Following the completion of the sale, the chief executive officer now owns 235,807 shares in the company, valued at approximately $6,529,495.83. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Steve E. Krognes sold 30,000 shares of Denali Therapeutics stock in a transaction dated Monday, September 30th. The shares were sold at an average price of $29.03, for a total value of $870,900.00. Following the sale, the director now owns 29,096 shares of the company’s stock, valued at approximately $844,656.88. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 7.90% of the stock is owned by corporate insiders.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.